Daré Bioscience, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2016 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.0M | $9.8K | $2.8M | $10.0M | $0 | $766.0K | $80.0K | $6.0K |
| Cost of Revenue | $295.8K | $0 | — | — | — | — | — | — |
| Gross Profit | $734.4K | $9.8K | — | — | — | — | — | — |
| Gross Margin | 71.3% | 100.0% | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $5.5M | $14.3M | $21.5M | $30.0M | $30.6M | $72.7K | $11.8M | $9.7M |
| SG&A Expense | $8.8M | $9.2M | $12.1M | $11.2M | $8.4M | $157.9K | $8.6M | $6.2M |
| Operating Income | $-13.6M | $-23.5M | $-30.9M | $-31.4M | $-39.1M | $-630.6K | — | — |
| Operating Margin | -1,315.5% | -239,692.2% | -1,101.9% | -313.9% | — | -82.3% | — | — |
| Interest Expense | — | — | — | — | — | $42.1K | $1.1M | $1.5M |
| Pretax Income | $-13.5M | $-4.1M | $-30.2M | $-30.9M | $-38.7M | $-673.0K | — | — |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | — | — | — |
| Net Income | $-13.4M | $-4.1M | $-30.2M | $-30.9M | $-38.7M | $-672.7K | $-23.3M | $-17.1M |
| Net Margin | -1,300.7% | -41,430.9% | -1,074.2% | -309.5% | — | -87.8% | -29,177.5% | -285,716.7% |
| EPS (Basic) | $-1.20 | $-0.48 | $-4.15 | $-0.37 | $-0.63 | $-0.41 | $-0.20 | $-3.13 |
| EPS (Diluted) | $-1.20 | $-0.48 | $-4.15 | $-0.37 | $-0.63 | $-0.41 | $-0.20 | $-3.13 |
| Shares Outstanding (Basic) | 11.2M | 8.5M | 7.3M | 84.6M | 61.2M | 1.7M | 161.0M | 6.3M |
| Shares Outstanding (Diluted) | 11.2M | 8.5M | 7.3M | 84.6M | 61.2M | 1.7M | 161.0M | 6.3M |
| Dividends Per Share | — | — | — | — | — | — | — | — |